Beam Therapeutics (BEAM) Research & Development (2019 - 2026)

Beam Therapeutics (BEAM) has reported Research & Development for 8 consecutive years, with $104.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development rose 5.78% year-over-year to $104.5 million; the TTM figure through Mar 2026 stood at $415.3 million (up 8.85% YoY), while the FY2025 annual figure was $409.6 million, up 11.44% from the prior year.
• Research & Development grew to $104.5 million in Q1 2026 per BEAM's latest filing, from $99.3 million in the prior quarter.
• Across five years, Research & Development topped out at $140.1 million in Q4 2023 and bottomed at $65.4 million in Q1 2022.
• Historically, Research & Development has averaged $95.9 million across 5 years, with a median of $98.8 million in 2025.
• On a YoY basis, Research & Development climbed as much as 63.58% in 2022 and fell as far as 65.59% in 2022.
• Beam Therapeutics' Research & Development stood at $86.3 million in 2022, then soared by 62.24% to $140.1 million in 2023, then dropped by 27.58% to $101.4 million in 2024, then decreased by 2.14% to $99.3 million in 2025, then climbed by 5.29% to $104.5 million in 2026.
• Business Quant data shows BEAM's Research & Development at $104.5 million in Q1 2026, $99.3 million in Q4 2025, and $109.8 million in Q3 2025.